Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Cardinal Health (CAH)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurocrine (NBIX – Research Report) and Cardinal Health (CAH – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Neurocrine (NBIX)
Oppenheimer analyst Jay Olson maintained a Buy rating on Neurocrine today and set a price target of $192.00. The company’s shares closed last Friday at $141.12.
According to TipRanks.com, Olson is a 5-star analyst with an average return of
Currently, the analyst consensus on Neurocrine is a Strong Buy with an average price target of $185.13, implying a 35.7% upside from current levels. In a report issued on January 22, TipRanks – xAI also upgraded the stock to Buy with a $152.00 price target.
See the top stocks recommended by analysts >>
Cardinal Health (CAH)
In a report released today, Erin Wright from Morgan Stanley maintained a Buy rating on Cardinal Health, with a price target of $255.00. The company’s shares closed last Friday at $229.37.
According to TipRanks.com, Wright is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cardinal Health with a $247.42 average price target, a 9.4% upside from current levels. In a report released yesterday, TipRanks – DeepSeek also upgraded the stock to Buy with a $229.00 price target.
